NCT00582894

Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: University of Oklahoma · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases

Detailed description

Primary Endpoints: 1. Engraftment of donor cells 2. Regimen related toxicities Secondary Endpoints: 1. Disease-free survival 2. Overall survival

Conditions

• Hematological Neoplasms
• Hematopoietic Stem Cell Transplantation

Interventions

Type	Name	Description
DRUG	Busulfex, Fludarabine, ALemtuzumab	Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1

Timeline

• Start date: 2005-02-01
• Primary completion: 2008-03-01
• Completion: 2008-03-01
• First posted: 2007-12-28
• Last updated: 2011-04-22
• Results posted: 2011-04-22

Locations

1 site across 1 country: United States